SG11201507571TA - Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structure - Google Patents
Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structureInfo
- Publication number
- SG11201507571TA SG11201507571TA SG11201507571TA SG11201507571TA SG11201507571TA SG 11201507571T A SG11201507571T A SG 11201507571TA SG 11201507571T A SG11201507571T A SG 11201507571TA SG 11201507571T A SG11201507571T A SG 11201507571TA SG 11201507571T A SG11201507571T A SG 11201507571TA
- Authority
- SG
- Singapore
- Prior art keywords
- dengue virus
- rna structure
- sirna
- composition
- double helix
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130079310 | 2013-07-05 | ||
| PCT/KR2014/006032 WO2015002512A1 (en) | 2013-07-05 | 2014-07-04 | Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507571TA true SG11201507571TA (en) | 2015-10-29 |
Family
ID=52144017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507571TA SG11201507571TA (en) | 2013-07-05 | 2014-07-04 | Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structure |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9695421B2 (en) |
| EP (1) | EP3018210A4 (en) |
| JP (1) | JP6368363B2 (en) |
| KR (1) | KR101715228B1 (en) |
| CN (1) | CN105705639A (en) |
| AU (1) | AU2014284835B2 (en) |
| CA (1) | CA2917318A1 (en) |
| MX (1) | MX2016000021A (en) |
| SG (1) | SG11201507571TA (en) |
| WO (1) | WO2015002512A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3018294A1 (en) * | 2016-06-01 | 2017-12-07 | Excision Biotherapeutics, Inc. | Compositions and methods of treatment for lytic and lysogenic viruses |
| KR101888104B1 (en) * | 2016-10-12 | 2018-08-14 | 사회복지법인 삼성생명공익재단 | MET exon 14 skipping specific siRNA and pharmaceutical composition for preventing or treating of cancer containing the same |
| KR101986188B1 (en) | 2017-07-12 | 2019-06-07 | 서울대학교산학협력단 | Identifying method and kit for activity of rna dependent rna polymerase |
| KR102473989B1 (en) * | 2018-11-28 | 2022-12-07 | (주)바이오니아 | Double-stranded oligo nucleotide structure comprising androgen receptor specific sequences and composition comprising the same for preventing hair loss and hair growth |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| CA2159626C (en) | 1993-04-02 | 2001-10-02 | Lingna Li | Method for delivering beneficial compositions to hair follicles |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| US6175001B1 (en) | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
| EP2278012B1 (en) | 2000-02-16 | 2015-08-26 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Immunogenic Dengue 2 virus chimeras |
| US20030224353A1 (en) * | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US8796235B2 (en) * | 2003-02-21 | 2014-08-05 | University Of South Florida | Methods for attenuating dengue virus infection |
| WO2005030800A2 (en) | 2003-08-05 | 2005-04-07 | Avi Biopharma, Inc. | Oligonucleotide analog and method for treating flavivirus infections |
| EP2308887A3 (en) | 2003-11-12 | 2011-07-13 | Bayer HealthCare LLC | Oligonucleotides and methods for detection of west nile virus |
| ATE555202T1 (en) | 2004-08-16 | 2012-05-15 | Immune Disease Inst Inc | METHOD FOR DELIVERING RNA INTERFERENCE AND USES THEREOF |
| EP1812494A1 (en) | 2004-09-29 | 2007-08-01 | Alza Corporation | Microparticles and nanoparticles containing a lipopolymer |
| TWI386225B (en) | 2004-12-23 | 2013-02-21 | Alcon Inc | Rnai inhibition of ctgf for treatment of ocular disorders |
| AU2006280600B2 (en) * | 2005-08-17 | 2012-01-19 | Bioneer Corporation | Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| WO2007044468A2 (en) * | 2005-10-05 | 2007-04-19 | The Cbr Institute For Biomedical Research, Inc. | Method to treat flavivirus infection with sirna |
| JP2010507387A (en) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
| CA2675834A1 (en) | 2007-01-16 | 2008-07-24 | Proteologics, Ltd. | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
| WO2010042823A1 (en) | 2008-10-09 | 2010-04-15 | Northeastern Universtiy | Multifunctional self-assembling polymeric nanosystems |
| CN104922676B (en) * | 2009-03-20 | 2019-03-12 | Clsn实验室股份有限公司 | Polyamine derivatives |
| KR101224828B1 (en) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | SiRNA conjugate and preparing method thereof |
| WO2011000106A1 (en) * | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
| AR078921A1 (en) | 2009-11-09 | 2011-12-14 | Hoffmann La Roche | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES OF THE QUINESINAS SUPERFAMILY, KIF10 |
| US20110206617A1 (en) * | 2010-02-22 | 2011-08-25 | Krishnendu Roy | Modified polysaccharides for drug and contrast agent delivery |
| US9328347B2 (en) * | 2011-07-18 | 2016-05-03 | Oregon Health & Science University | siRNA useful in the treatment of flavivirus infection |
| CN110372673B (en) | 2011-07-29 | 2023-10-03 | 卡尔约药物治疗公司 | Hydrazide-containing nuclear transport modulators and uses thereof |
| EP3960726A1 (en) | 2011-10-18 | 2022-03-02 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
| GB201119028D0 (en) * | 2011-11-04 | 2011-12-14 | Epistem Ltd | Dengue assay |
| ES2899043T3 (en) | 2011-12-15 | 2022-03-09 | Bioneer Corp | Novel oligonucleotide conjugates and their use |
| BR112014016562B1 (en) | 2012-01-05 | 2021-08-10 | Bioneer Corporation | DOUBLE HELIX OLIGO-RNA STRUCTURE, NANOPARTICLE AND PREPARATION METHOD |
| KR101392973B1 (en) | 2012-10-15 | 2014-05-09 | (주)바이오니아 | siRNA conjugate and preparing method thereof |
-
2014
- 2014-07-04 WO PCT/KR2014/006032 patent/WO2015002512A1/en active Application Filing
- 2014-07-04 CA CA2917318A patent/CA2917318A1/en not_active Abandoned
- 2014-07-04 SG SG11201507571TA patent/SG11201507571TA/en unknown
- 2014-07-04 KR KR1020157024212A patent/KR101715228B1/en active IP Right Grant
- 2014-07-04 AU AU2014284835A patent/AU2014284835B2/en not_active Expired - Fee Related
- 2014-07-04 CN CN201480048987.2A patent/CN105705639A/en active Pending
- 2014-07-04 US US14/902,564 patent/US9695421B2/en active Active
- 2014-07-04 EP EP14820482.9A patent/EP3018210A4/en not_active Withdrawn
- 2014-07-04 MX MX2016000021A patent/MX2016000021A/en unknown
- 2014-07-04 JP JP2016523669A patent/JP6368363B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2917318A1 (en) | 2015-01-08 |
| KR101715228B1 (en) | 2017-03-13 |
| JP6368363B2 (en) | 2018-08-01 |
| EP3018210A4 (en) | 2017-06-07 |
| MX2016000021A (en) | 2017-04-06 |
| US9695421B2 (en) | 2017-07-04 |
| KR20150143425A (en) | 2015-12-23 |
| AU2014284835A1 (en) | 2016-02-18 |
| AU2014284835B2 (en) | 2017-08-10 |
| US20160145622A1 (en) | 2016-05-26 |
| JP2016524901A (en) | 2016-08-22 |
| CN105705639A (en) | 2016-06-22 |
| WO2015002512A1 (en) | 2015-01-08 |
| EP3018210A1 (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269662A (en) | Inhibitors of hepatitis c virus | |
| HK1248278A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| IL241294A0 (en) | Dendritic cell response gene expression, compositions of matters and methods of use thereof | |
| HK1220388A1 (en) | Uridine nucleoside derivatives, compositions and methods of use | |
| HK1219500A1 (en) | Genetically stable oncolytic rna virus, method of manufacturing and use thereof rna | |
| PL2988764T3 (en) | Anti-dandruff compositions, and methods of use thereof | |
| SG11201507571TA (en) | Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structure | |
| EP3013852A4 (en) | Methods and compositions for dengue virus vaccines | |
| SG11201510266SA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| SG11201505930TA (en) | Porcine parvovirus 5b, methods of use and vaccine | |
| EP2985286A4 (en) | Midbody of ticagrelor and preparation method therefor, and preparation method for ticagrelor | |
| EP2807256A4 (en) | Myonectin (ctrp15), compositions comprising same, and methods of use | |
| HK1222195A1 (en) | Catalyst compositions and methods of preparing them | |
| BR112014031508A2 (en) | concentrated food composition, process and use of composition | |
| HK1219904A1 (en) | Novel vaccines against multiple subtypes of dengue virus | |
| EP2950810A4 (en) | A method of virus inactivation in composition comprising factor vii | |
| IL244464B (en) | Semaphorin 3c variants, compositions comprising said variants and methods of use thereof | |
| HK1216006A1 (en) | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof | |
| HK1204001A1 (en) | Rna fragment, preparation method therefor, and use thereof rna | |
| FIU20110165U0 (en) | An expulsion of deer, hares and browns |